All Blogs

Oct 07, 2024

After more than ten years without significant therapeutic advancements in chronic obstructive pulmonary disease (COPD), patients with this progressive condition now have two new treatment options, with more likely to follow. Regeneron and Sanofi recently announced that the FDA has broadened the use of the highly...

Oct 04, 2024

Trispecific antibodies are the next frontier in targeted cancer therapy, offering a powerful new approach to treating complex diseases. These innovative antibodies are designed to bind to three different antigens simultaneously, enhancing treatment precision. By engaging multiple targets at once, trispecific antibo...

Oct 03, 2024

Establishment Labs Received U.S. FDA Approval for Motiva Implants On September 26, 2024, Establishment Labs Holdings Inc., a global medical technology company focused on enhancing women’s health and wellness, particularly in breast aesthetics and reconstruction, announced that it received approval from the U.S. ...

Oct 02, 2024

With millions of cases diagnosed globally each year, gastrointestinal cancers represent a significant health challenge but also an opportunity for breakthroughs in targeted therapies and personalized medicine. Gastrointestinal cancers refer to a group of cancers that affect the digestive system, including the esoph...

Oct 01, 2024

IntraBio's AQNEURSA Receives Historic FDA Approval for Niemann-Pick Disease Type C Treatment IntraBio Inc. has received approval from the FDA for AQNEURSA (levacetylleucine), marking a significant milestone in the treatment of neurological manifestations of Niemann-Pick disease type C  in both adults and pe...

Oct 14, 2025

After years of little progress in the field of schizophrenia drug treatment, Bristol Myers Squibb’s USD 14 billion acquisition of Karuna Therapeutics has paid off with the approval of a groundbreaking new drug. BMS’s novel medication, KarXT—now named COBENFY—received FDA approval on 26 September 2024 for the treatm...

Jun 10, 2025

Imagine a world where treatment options are as precise as a scalpel and as adaptable as a chameleon. Bispecific antibodies are paving the way for this future, bringing revolutionary advancements in oncology and various therapeutic fields. By harnessing the power of these dual-targeting agents, researchers are unloc...

Sep 27, 2024

On 11 September 2024, the latest results from the FLOW trial were presented at the European Association for the Study of Diabetes (EASD) conference in Madrid, Spain. The FLOW trial, initiated in 2019, was a global, multinational, randomized controlled trial conducted across 28 countries, 387 sites, and 3,533 partic...

Sep 27, 2024

Data from an integrated pooled analysis of finerenone across three Phase III trials involving heart failure, chronic kidney disease (CKD), and Type 2 diabetes (T2D) was presented at the 2024 European Association for the Study of Diabetes (EASD) Congress. This analysis was conducted with data from the FIDELIO-DKD2 a...

Sep 26, 2024

Vivos Therapeutics Received Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring On September 18, 2024, Vivos Therapeutics, Inc., a premier medical device and technology firm focused on innovative treatments for sleep-related breathing disorders (SRBDs), including obs...